Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126016371 | 12601637 | 1 | I | 20141119 | 20160712 | 20160728 | 20160728 | EXP | DK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-058906 | BRISTOL MYERS SQUIBB | 37.37 | YR | F | Y | 0.00000 | 20160728 | CN | DK | DK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126016371 | 12601637 | 1 | PS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 30 MG, UNK | U | 21436 | 30 | MG | |||||||
| 126016371 | 12601637 | 2 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 15 MG, UNK | U | 21436 | 15 | MG | |||||||
| 126016371 | 12601637 | 3 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 30 MG, UNK | U | 21436 | 30 | MG | |||||||
| 126016371 | 12601637 | 4 | SS | QUETIAPIN ACCORD | QUETIAPINE | 1 | Oral | 25 MG, UNK | U | 0 | 25 | MG | TABLET | ||||||
| 126016371 | 12601637 | 5 | SS | TOLMIN | MIANSERIN HYDROCHLORIDE | 1 | Oral | 20 MG, UNK | U | 0 | 20 | MG | |||||||
| 126016371 | 12601637 | 6 | SS | MIANSERIN MYLAN | MIANSERIN | 1 | Oral | 20 MG, UNK | U | 0 | 20 | MG | |||||||
| 126016371 | 12601637 | 7 | SS | LAMOTRIGIN STADA | LAMOTRIGINE | 1 | Oral | 300 MG, UNK | U | 0 | 300 | MG | |||||||
| 126016371 | 12601637 | 8 | SS | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 400 MG, UNK | 0 | 400 | MG | ||||||||
| 126016371 | 12601637 | 9 | SS | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 200 MG, UNK | 0 | 200 | MG | ||||||||
| 126016371 | 12601637 | 10 | SS | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 150 MG, UNK | 0 | 150 | MG | ||||||||
| 126016371 | 12601637 | 11 | SS | MELATONIN | MELATONIN | 1 | Oral | 3 MG, QD | U | 0 | 3 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126016371 | 12601637 | 1 | Restlessness |
| 126016371 | 12601637 | 2 | Mental disorder |
| 126016371 | 12601637 | 4 | Depression |
| 126016371 | 12601637 | 5 | Depression |
| 126016371 | 12601637 | 6 | Depression |
| 126016371 | 12601637 | 7 | Restlessness |
| 126016371 | 12601637 | 8 | Schizophrenia |
| 126016371 | 12601637 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126016371 | 12601637 | OT |
| 126016371 | 12601637 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126016371 | 12601637 | Amenorrhoea | |
| 126016371 | 12601637 | Apathy | |
| 126016371 | 12601637 | Communication disorder | |
| 126016371 | 12601637 | Depressed mood | |
| 126016371 | 12601637 | Disturbance in attention | |
| 126016371 | 12601637 | Dry mouth | |
| 126016371 | 12601637 | Emotional poverty | |
| 126016371 | 12601637 | Fatigue | |
| 126016371 | 12601637 | Insomnia | |
| 126016371 | 12601637 | Loss of dreaming | |
| 126016371 | 12601637 | Memory impairment | |
| 126016371 | 12601637 | Menopausal symptoms | |
| 126016371 | 12601637 | Musculoskeletal stiffness | |
| 126016371 | 12601637 | Pollakiuria | |
| 126016371 | 12601637 | Product use issue | |
| 126016371 | 12601637 | Sleep phase rhythm disturbance | |
| 126016371 | 12601637 | Stress | |
| 126016371 | 12601637 | Suicidal ideation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126016371 | 12601637 | 4 | 20140129 | 0 |